United States : AbbVie Announces Phase 3 Study of VENCLEXTA/VENCLYXTO (venetoclax) in Combination with Rituxan (rituximab) Meets its Primary Endpoint.
AbbVie, a research and development based global biopharmaceutical company, today announced the first presentation of efficacy and safety results from MURANO, an international, multicenter, open-label, randomized Phase 3 study of VENCLEXTA/VENCLYXTO (venetoclax) in combination with Rituxan (rituximab) compared with bendamustine in combination with Rituxan in patients with relapsed or refractory (R/R) chronic lymphocytic leukemia (CLL).
Investigator-assessed results showed that patients with R/R CLL achieved significantly prolonged median progression-free survival (PFS) with VENCLEXTA/VENCLYXTO in combination with Rituxan median PFS, not reached , compared with bendamustine in combination with Rituxan median PFS, 17.0 months; hazard ratio, 0.17; 95% CI, 0.110.25; P
[c] 2017 Al Bawaba (Albawaba.com) Provided by SyndiGate Media Inc. ( Syndigate.info ).
|Printer friendly Cite/link Email Feedback|
|Article Type:||Clinical report|
|Date:||Dec 15, 2017|
|Previous Article:||United States : IMBRUVICA (ibrutinib) Data Provide Insights Into Its Potential Treatment Benefits for Previously-Treated Chronic Graft-Versus-Host...|
|Next Article:||Germany : RDM reduces costs and improves quality and productivity on BM 3 after rebuild project with Voith.|